Non-Small Cell Lung Cancer

Midwest CEPAC

Lung cancer is the number one cause of cancer death in the United States, expected to cause 158,000 deaths in 2016, and accounting for 26.5% of all cancer deaths. It is the second most common cancer in both men (after prostate cancer) and women (after breast cancer), with 118,000 and 106,000 new cases expected in 2016, respectively. Lung cancer includes different pathological types, broadly divided into small-cell lung cancer and non-small-cell lung cancer (NSCLC). NSCLC makes up about 85% of lung cancers and comprises mainly squamous cell carcinoma, adenocarcinoma, and large-cell lung cancer. Stage at diagnosis is a primary factor in patient survival, and patients with NSCLC commonly present with advanced disease.

Interventions of Interest:

Tyrosine kinase inhibitors:
  • Afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceuticals, Inc.)
  • Erlotinib (Tarceva®, Genentech, Inc. and Astellas Pharma US, Inc.)
  • Gefitinib (Iressa®, AstraZeneca)
Immunotherapies targeting the programmed death 1 (PD-1) receptor or its ligand (PD-L1):
  • Atezolizumab (Tecentriq®, Genentech, Inc., Roche Group)
  • Nivolumab (Opdivo®, Bristol-Meyers Squibb Co.)
  • Pembrolizumab (Keytruda®, Merck & Co.)

Date of Review: October 2016

Associated Meetings

October 20, 2016

Century BC Room,  Millennium Student Center, University of Missouri-St. Louis
1 University Blvd, St. Louis, MO 63121

The Midwest CEPAC convened in October 2016 to discuss ICER's report on treatments for non-small cell lung cancer.


Key Dates

Associated Materials

06/21/2016

This document was open to a three-week public comment period. Comments received were incorporated into a revised scoping document.


07/15/2016

07/19/2016

07/19/2016

08/19/2016

08/19/2016

09/29/2016

09/29/2016

09/29/2016

Comment received on draft evidence report.


09/29/2016

10/20/2016

10/20/2016

Public Meeting of the Midwest CEPAC.